Cite
HARVARD Citation
Signoriello, E. et al. (2022). Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. Multiple sclerosis. pp. 93-101. [Online].